Fabtech Technologies Limited

About the company

Fabtech Technologies Limited is a turnkey engineering solutions company with operations in 62 countries, including the Middle East, Africa, Asia, Europe, and North America. The company is focused on developing and delivering end-to-end projects for the pharmaceutical, biotech, and healthcare industries, with capabilities ranging from clean air, clean water and process systems. Its portfolio includes greenfield and brownfield projects with end-to-end services ranging from disease profiling and facility design through procurement, installation, validation, to regulatory compliance. The company follows an asset-light business model, acquiring equipment from related parties and third-party vendors, which enables it to concentrate on execution and project management. An in-house digital project management tool, FabAssure, increases efficiency by providing real-time monitoring, accelerating issue resolution, and transparency throughout the project cycle. The company had a robust order book of ₹904.42 crore as of July 31, 2025. Overseas operations contributed 85.71% of FY25 revenues. The order book of Fabtech has significantly diversified, increasing from ₹424.65 crore in FY23 to ₹761.74 crore in FY25, dominated by large turnkey orders, accounting for 96.74% of orders in FY25. The Middle East and North Africa (MENA) region accounted for 38.87% of orders in FY25; the ECO Zone and GCC regions contributed 26.85% and 17.99%, respectively. The company's top five projects generated 56% of revenue in FY25, demonstrating established relationships. The revenue mix of the company highlights its strength in turnkey projects, which accounted for 75.51% of FY25. Standalone services like equipment supply and logistics accounted for 24.49%. Fabtech has also ventured out of pharmaceuticals into nutraceuticals and GMP-certified FMCG businesses, with pharmaceuticals, healthcare and biotech accounting for 73.96% of revenues and non-pharma customers accounting for 26.04% of revenues in FY25, from a mere 5.65% in FY24. Fabtech has made investments in processes that are ISO certified, with adherence to ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 standards. The global pharmaceutical market is expected to sustain a 5.5-6.5% CAGR from 2024 to 2029 to reach ~$2,100 to $2,200 billion by 2029, and the pharmaceuticals market in the MEA (Middle Eastern and African) region is estimated to log a 4.5-5.5% CAGR from 2024 to 2029. Growth is underpinned by the rising prevalence of chronic and lifestyle diseases, an ageing global population, and stronger demand for generics and precision medicine. The company, with an established presence across 62 countries, and a revenue contribution of 38.87% from the MENA region, 26.85% from the ECO zone and 17.99% from the GCC region in FY25, is well positioned to capitalise on these trends. The company’s strategies include expanding in existing regions through its overseas subsidiary or joint ventures to establish local presence, pursuing inorganic growth through acquisitions in India, the United Arab Emirates, Saudi Arabia and Egypt and diversifying its customer base. It is also intending to increase its clientele in the African region, which has limited pharmaceutical and healthcare infrastructure. Now, Fabtech Technologies Limited is launching its initial public offering (IPO), which consists of a fresh issue of over 1.2 crore shares worth ₹230.35 crore. Its shares will be listed on the NSE and BSE.

Financial performance (₹ Cr)

Subscription breakup (final, times)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   29 Sept 2025

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   01 Oct 2025

   Last day to place your bid

3. Basis of Allotment

   Completed
   03 Oct 2025

   Share allotment finalised

4. Refund Initiation

   Completed
   06 Oct 2025

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   06 Oct 2025

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   07 Oct 2025

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.